ATLANTA, Aug. 23, 2017 /PRNewswire/ -- MMJ Labs, LLC, a global leader in noninvasive pain relief medical devices, announced today it has been awarded another patent from the United States Patent and Trademark Office relating to their novel pain management platform, US Patent No. 9,358,152.
MMJ Labs expanded patent portfolio is supported by the extensive clinical research demonstrating synergistic effects of thermal and vibrational stimulation. VibraCool® vibrational cryotherapy device is being used not only for muscle recovery but for chronic pain relief and to avoid opioids. The research underpinning the patent filings shows vibration speeds repair at a cellular level.
Cool-Pulse™ technology, developed in part with funding from the NIH Small Business Innovative Research program, combines high frequency, low amplitude vibration and a thermal treatment pack that can add cooling to disrupt nerve impulses of pain. Additional patent applications are pending for this technology.
"We are thrilled about the profound effects our straightforward reusable technology can have on reducing pain medication dependence," said Amy Baxter MD, founder and CEO of MMJ Labs. "Understanding the multiple ways that vibration and thermal sources can interact directly to alter nerve signals is a huge step forward for post-surgical pain management, sports recovery, and chronic pain." Baxter notes supporting research by Lam et al., Fillipi et al., Peer et al., and Imtiyaz et al., among others.
To learn more about VibraCool®, visit www.VibraCool.com, or the needle pain reduction product line Buzzy® and DistrACTION® cards at www.buzzyhelps.com. Engage in conversations about pain relief with VibraCool on Facebook, Twitter and Instagram.
About MMJ Labs, LLC
MMJ Labs, LLC, based in Atlanta, Georgia, is a woman-owned small business (WOSB) researching, developing, and delivering quality pain relief medical devices to hospitals and patients worldwide. MMJ Labs products have unique FDA product codes as Class I medical devices, with CE clearance and acceptance by ANVISA, KFDA, and Australia and New Zealand health boards. For more information, see www.MMJLabs.com.
Dr. Amy Baxter
SOURCE MMJ Labs, LLC